ProKidney Corp
NASDAQ:PROK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BRF SA
NYSE:BRFS
|
BR |
|
A
|
Acroud AB
STO:ACROUD
|
SE |
|
C
|
Coastalsouth Bancshares Inc
OTC:COSO
|
US |
|
K
|
Kyowa Leather Cloth Co Ltd
TSE:3553
|
JP |
|
J
|
Jiangsu New Energy Development Co Ltd
SSE:603693
|
CN |
|
Hengtai Securities Co Ltd
HKEX:1476
|
CN |
|
Just Dial Ltd
NSE:JUSTDIAL
|
IN |
|
Dynagas LNG Partners LP
NYSE:DLNG
|
MC |
|
G
|
Gopeng Bhd
KLSE:GOPENG
|
MY |
|
Indigo Books and Music Inc
TSX:IDG
|
CA |
|
Tempur Sealy International Inc
NYSE:TPX
|
US |
ProKidney Corp
Other
ProKidney Corp
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
ProKidney Corp
NASDAQ:PROK
|
Other
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
ProKidney Corp
Glance View
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.
See Also
What is ProKidney Corp's Other?
Other
0
USD
Based on the financial report for Dec 31, 2025, ProKidney Corp's Other amounts to 0 USD.
